Wild-type (senile) amyloidosis other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(8 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Wild-type (senile) amyloidosis}}
{{Wild-type (senile) amyloidosis}}
{{CMG}}
{{CMG}}{{AE}}{{ADG}}


==Overview==
==Overview==
Other [[Diagnosis|diagnostic]] studies that help in [[Diagnosis|diagnosing]] wild-type (senile) amyloidosis include [[Histopathology|histopathological]] [[analysis]] and [[genetic testing]].


==Other Diagnostic Studies==
==Other Diagnostic Studies==
<br /><br />
Other [[Diagnosis|diagnostic]] studies that help in [[Diagnosis|diagnosing]] wild-type (senile) amyloidosis include [[Histopathology|histopathological]] [[analysis]] and [[genetic testing]].<ref name="pmid23964755">{{cite journal |vauthors=Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, Hittinger L, Loric S, Lefaucheur JP, Plante-Bordeneuve V |title=Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis |journal=Amyloid |volume=20 |issue=4 |pages=212–20 |date=December 2013 |pmid=23964755 |doi=10.3109/13506129.2013.825240 |url=}}</ref>
 
=== Nuclear imaging ===
Nuclear imaging has emerged as important non-invasive tool in the diagnosis of suspected ATTR cardiac amyloidosis due to wide availability at a low cost, having few contraindications and the capacity to differentiate from other cardiomyopathies. Bone-avid tracers, like 99mTc-DPD (technetium-3,3-diphosphono-1,2-propanodicar-boxylic acid), 99mTc-PYP (technetium-pyrophosphate) and 99mTc-HMDP [technetium-hydroxymethylene diphosphonate (Tc-HMDP)] have been shown to have high sensitivity and specificity for differentiating patients with ATTR CA, irrespective of genotype, from patients with AL-CA or others with HFpEF (32-37). The exact mechanism by which these radiotracers differentially accumulate in myocardium is not completely clear but may be due to differences in deposited amyloid proteins (38,39), higher calcium levels seen during the repair process (40) and/or higher degree of tissue microcalcifications in ATTR compared to AL cardiac amyloidosis (41). Irrespective of the mechanism, an international consensus document has confirmed that the combination of grade 2 or 3 cardiac uptake on a bone-avid tracer scan in the setting of absent monoclonal protein by serum immunofixation electrophoresis (IFE), urine IFE, and serum free light chain assay is diagnostic of ATTR cardiac amyloidosis as compared to AL-CA or other wall thickening diseases (42). Bokhari ''et al.'' (37) described a standardized imaging protocol using 99mTc-PYP to diagnose ATTR CA using Heart/Contralateral ratio ≥1.5. Nuclear imaging with 99mTc-DPD (43) and 99mTc-PYP (44) can diagnose the presence of cardiac involvement prior to any overt echocardiographic abnormalities and can predict major adverse cardiac events (34,35,39,43). Future studies are needed to establish the role of bone-avid nuclear tracers for the early identification of ATTRwt-CA, differentiating it from ATTRm-CA (confirmed by genetic testing) and evaluation of subsequent outcomes.
 
Scintigraphy imaging, which is inherently qualitative, falls short of being able to quantify the radioactivity at the affected sites thus cannot be used in assessing disease burden and response to therapy. Positron emission tomography (PET) is a nuclear modality that can circumvent this problem, emerging as a promising tool in the monitoring and management of cardiac amyloidosis. Recently discovered amyloid binding PET tracers 18-F florbetapir (45,46) and 11C-Pittsburgh compound B (PiB) (47,48) can identify both AL and ATTR cardiac amyloidosis. Case reports have shown cardiac uptake of another PET tracer [18F]-sodium fluoride only in patients with ATTRwt-CA and ATTRm-CA, but not in ones with AL-CA (49,50).
 
=== Cardiovascular magnetic resonance ===
CMR is an important diagnostic and prognostic tool for cardiac amyloidosis. Various techniques utilizing different tissue imaging timing, with and/or without gadolinium contrast, and strain can provide detailed information about the presence, location, and distribution of hypertrophy, as well as cardiac function. One major drawback of using CMR is that gadolinium contrast is contraindicated in patients with moderate to severe kidney disease.
 
T1 sequence of CMR, a composite measure of extracellular matrix and myocardial cells, with the use of gadolinium can help differentiate extracellular tissue thickening due to myocardial hypertrophy ''vs.'' extracellular deposition. Utilizing pre- and post-contrast T1 mapping, extracellular volume (ECV) can be calculated and is a direct measurement of the cardiac interstitium (51). ECV expansion can detect amyloid fibrils infiltration in AL and ATTR cardiac amyloidosis earlier than conventional testing and is quantitative marker of the amyloid burden lending itself with the potential use in early diagnosis and disease monitoring (52,53). Marked increased non-contrast T1 relaxation times also seen in patients who have interstitial infiltration by amyloid fibrils and has good correlation with disease severity, future prognosis, and the potential to track changes over time (from natural progression or disease modifying therapy) (54-56). One of the major advantages of T1 mapping is that it does not require contrast which is contraindicated in advanced kidney disease, however, currently this technique has limited clinical availability due to technical challenges related to sequence- and vendor-specific differences (57,58).
 
The myocardial deposition of amyloid fibrils in ATTR-CA increases ECV which serves as a reservoir for gadolinium accumulation leading to characteristic continuum of late gadolinium enhancement (LGE) (59). In the early stages of the disease there usually is no LGE enhancement that progresses to subendocardial and finally transmural (in non-ischemic pattern) LGE enhancement at the late stages (''Figure 2''), which also tracks with increasing ECV and a worse prognosis (58,60). In contrast, a diffuse-subendocardial patterns is most commonly described in AL-CA disease (58,60), which has led to CMR based LGE scoring system that seems to differentiate between ATTR and AL cardiomyopathies (61). Future studies are necessary to establish similarities and differences between the LGE in patients with ATTRm-CA and ATTRwt-CA.
 
Traditional LGE imaging technique depends on normal myocardium to enhance the diseased area and has been limited in ATTR-CA due to difficult nulling, which have led to early and advanced disease misclassification. Phase-sensitive inversion recovery (PSIR) sequence that reduces the need for an optimal null point setting [initially described CMR evaluation of myocardial infarction (62)] makes LGE assessment in cardiac amyloidosis faster and operator-independent (58).
 
Feature tracking software applied to cine CMR datasets for assessment of left ventricular strain has shown good agreement between CMR and 2D Echo-derived myocardial longitudinal strain measurements (63) with apical sparing in longitudinal strain (64).
 
<br />
 
<br />
{| class="wikitable"
{| class="wikitable"
|+
|+
! colspan="2" |Other Diagnostic Studies
! colspan="2" |Other Diagnostic Studies
|-
|-
|Cardiac biomarkers
!Histopathological analysis
|
* Brain natriuretic peptide (BNP), N-terminal fragment of BNP (NT-proBNP) and cardiac troponins.
* Elevation of NT-proBNP indicates the presence of left ventricular abnormalities in patients with familial mutation in ATTR
* Used as a screening test to initiate workup for ATTRm-CA
* Increasing serum levels of BNP, NT-proBNP and troponins were shown to have a progressive correlation with disease severity and worse outcomes
* Monitoring of these cardiac biomarkers is being employed to monitor treatment
|-
|Histopathological diagnosis
|
|
* EMB with histopathology remains the gold standard for diagnosis of cardiac amyloidosis.
*[[Endomyocardial biopsy|Endomyocardial biopsy (EMB)]] with [[histopathology]] remains the [[Gold standard (test)|gold standard]] for [[diagnosis]] of cardiac amyloidosis.
* Histopathology demonstrates deposition of amorphous deposits of amyloid fibrils in the heart.  
*[[Histopathology]] demonstrates deposition of amorphous deposits of [[amyloid]] fibrils in the [[heart]].
* The binding of Congo red stain to the deposited amyloid fibrils leads to characteristic apple-green birefringence under polarized light microscopy and an intense yellow-green fluorescence is seen when binding to thioflavin.
* The binding of [[Congo red]] [[stain]] to the deposited [[amyloid]] fibrils leads to characteristic apple-green [[birefringence]] under polarized [[light microscopy]] and an intense yellow-green [[fluorescence]] is seen when binding to [[thioflavin]].
* Precursor protein identification can be accomplished by immunohistochemistry, electron microscopy, or mass spectrometry (preferred), depending upon institutional expertise.  
* Precursor [[protein]] identification can be accomplished by [[immunohistochemistry]], [[Electron microscope|electron microscopy]], or [[mass spectrometry]] (preferred), depending upon institutional expertise.
* Adjunctive laboratory tests to rule out AL include assaying for other organ dysfunction (e.g., proteinuria, alkaline phosphatase) and directly measuring the circulating light chains in plasma.
* Adjunctive [[laboratory]] [[Test|tests]] to rule out AL include assaying for other [[Organ (anatomy)|organ]] dysfunction (e.g., [[proteinuria]], [[alkaline phosphatase]]) and directly measuring the circulating [[Light chain|light chains]] in [[Blood plasma|plasma]].
* EMB is associated with risks of complications such as
*[[Endomyocardial biopsy|EMB]] is associated with risks of [[Complication (medicine)|complications]] such as:
** Ventricular free-wall perforation
**[[Ventricle (heart)|Ventricular]] free-wall [[perforation]]
** Arrhythmia  
**[[Cardiac arrhythmia|Arrhythmia]]
** Conduction abnormalities
**[[Electrical conduction system of the heart|Conduction]] abnormalities
|-
|-
|Genetic testing
!Genetic testing
|
|
* DNA sequencing for the transthyretin gene
*[[DNA]] sequencing for the [[transthyretin]] [[gene]]
* Absence of amino acid sequence abnormalities by mass spectrometry is consistent with ATTRwt-CA
* Absence of [[amino acid]] sequence abnormalities by [[mass spectrometry]] is consistent with wild-type (senile) amyloidosis
* Presence of a pathologic mutation  
* Presence of a [[Pathology|pathologic]] [[mutation]]
** Predict sites of organ involvement
** Predict sites of [[Organ (anatomy)|organ]] involvement
** Family history
**[[Family history]]
|}
|}


Latest revision as of 19:13, 20 December 2019

Wild-type (senile) amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Wild-type (senile) amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Wild-type (senile) amyloidosis other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Wild-type (senile) amyloidosis other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wild-type (senile) amyloidosis other diagnostic studies

CDC on Wild-type (senile) amyloidosis other diagnostic studies

Wild-type (senile) amyloidosis other diagnostic studies in the news

Blogs on Wild-type (senile) amyloidosis other diagnostic studies

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Wild-type (senile) amyloidosis other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.

Other Diagnostic Studies

Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.[1]

Other Diagnostic Studies
Histopathological analysis
Genetic testing

References

  1. ↑ Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, Hittinger L, Loric S, Lefaucheur JP, Plante-Bordeneuve V (December 2013). "Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis". Amyloid. 20 (4): 212–20. doi:10.3109/13506129.2013.825240. PMID 23964755.
Retrieved from "https://www.wikidoc.org/index.php?title=Wild-type_(senile)_amyloidosis_other_diagnostic_studies&oldid=1592577"